NCT02818738View on ClinicalTrials.gov

Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

February 7, 2021

Study Completion Date

February 11, 2021

Conditions

First Manifestation of Steroid Sensitive Nephrotic Syndrome

Interventions

DRUG

Levamisole Hydrochloride

Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months

OTHER

Placebo

matching verum

Trial Locations (1)

75019

Hôpital Robert Debré, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02818738 - Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children | Biotech Hunter | Biotech Hunter